Here are five things to know:
1. Every year, 33 percent of Americans suffer from a musculoskeletal condition that requires medical intervention. Direct medical costs approach $1 trillion annually. Despite the frequency of skeletal dysfunction, there are limited safe and effective bone growth factors in clinical use.
2. Notch is a cell-cell communication pathway that regulates self-renewal and differentiation within the mesenchymal/osteoblast lineage. Jagged-1 is the principal Notch ligand in bone.
3. Jagged-1 is an osteoinductive protein that positively regulates posttraumatic bone healing in animals and is a bone-anabolic agent with therapeutic potential for regenerating traumatic or congenital bone defects.
4. Notch gain-of-function using recombinant Jagged-1 protein on collagen scaffolds encourages the healing of craniofacial and appendicular surgical defects in mice and rats.
5. Localized delivery of Jagged-1 promotes bone apposition and defect healing and avoids the diffuse bone hypertrophy characteristic of the clinically problematic bone morphogenetic proteins.
More articles on biologics:
CartiHeal secures $2.5M from Bioventus, financing reaches $21M — 3 key insights
Dr. Thomas Vogl performs 1st cases of Triojection in Germany: 5 things to know
Osteo-P bone graft substitute receives 510(k) clearance: 6 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
